

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

RESPONSE TO SGX'S QUERY REGARDING TRADING ACTIVITY

Question 1: Are you (the issuer) aware of any information not previously announced concerning you, your subsidiaries or associated companies which, if known, might explain the trading? Such information may include events that are potentially material and price-sensitive, such as discussions and negotiations that may lead to joint ventures, mergers, acquisitions or purchase or sale of a significant asset. You may refer to paragraph 9 in Appendix 7A of the Catalist Rules for further examples.

- If yes, the information shall be announced immediately.

Company's response: The Company is not aware of any information not previously announced concerning the Company and its subsidiaries or associated companies which, if known, might explain the trading.

Question 2: Are you aware of any other possible explanation for the trading? Such information may include public circulation of information by rumours or reports.

Company's response: The Company is not aware of any other explanation for the trading, including any public circulation of information by rumours or reports.

The Company notes that its associated company, Biolidics Limited ("**Biolidics**") had called for a trading halt in the afternoon of 22 April 2020 and subsequently announced the appointment of Aytu Bioscience, Inc. as its exclusive distributor for Biolidics' Novel Coronavirus 2019 Rapid Test Kits in the United States of America on 23 April 2020. This trading halt was lifted in the afternoon of 23 April 2020, after the aforesaid announcement was released by Biolidics on SGXNET.

Question 3: Can you confirm your compliance with the listing rules and, in particular, Catalist Rule 703?

Company's response: The Company confirms that it is in compliance with the listing rules and, in particular, Catalist Rule 703.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

23 April 2020

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*